WA-T-MOBILE
25.4.2022 15:25:04 CEST | Business Wire | Press release
Today, T-Mobile (NASDAQ: TMUS) announced that Lucid Drone Technologies has chosen the Un-carrier to be the exclusive provider of IoT connectivity and management for their fleet of industrial spraying drones. Together, Lucid Drone Technologies and T-Mobile are collaborating to put maintenance teams and exterior cleaning companies out of harm’s way using drone technology for high-risk facilities maintenance work like exterior soft-wash cleaning and high-rise window washing. The companies also plan to leverage T-Mobile's industry-leading 5G network in the future to fly drones beyond line-of-sight and power more data-intensive capabilities like video streaming.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220424005109/en/
A game changer for safety of maintenance teams
Commercial property management firms and developers make significant investments to keep maintenance teams safe. Expensive liability insurance premiums and equipment fees have facilities leaders looking for new and cost-effective solutions. Enter industrial spraying drone pioneer Lucid Drone Technologies and the Un-carrier to deliver a game changer — drones equipped to clean exterior building surfaces and windows.
The next generation of Lucid Drone Technologies industrial spraying drones, powered by T-Mobile for Business, can perform exterior washing for commercial building surfaces and windows, including outdoor stadiums and arenas, hotels, and university structures. That means maintenance teams can steer clear of some high-risk tasks, keeping them safer and focused on other mission critical work.
IoT driving the future of industrial spraying drone technology
T-Mobile’s network powers critical capabilities for Lucid Drone Technologies industrial spraying drones such as real-time sharing of flight data, battery utilization information, hardware diagnostics, and delivery of firmware and software updates. Additionally, T-Mobile Control Center will give Lucid Drone Technologies the ability to view and manage the connectivity of their industrial spraying drones. With the automation and provisioning capabilities of T-Mobile’s IoT platform, Lucid Drone Technologies can easily accelerate deployment of their growing fleet. Lucid Drone Technologies will have near real-time visibility to all their industrial spraying drones with the ability to monitor network conditions and device behavior with T-Mobile Control Center.
Initially, T-Mobile for Business will deliver 4G LTE connectivity to Lucid Drone Technologies industrial spraying drones, providing a reliable connection nationwide. Lucid Drone Technologies expects to utilize the Un-carrier's 5G network in the near future for advanced use cases such as network operations center access, live streaming video and remote piloting. As Americas largest and fastest 5G network, T-Mobile is poised to push IoT to its full potential and catapult adoption — paving the way for new drone applications that rely on low-latency, high-speed data, and real-time location and proximity-based services.
"At Lucid Drone Technologies, we are committed to providing robotic solutions that allow our customers to complete jobs that were once dull, dirty, and dangerous in a safer, faster, and smarter way,” said Andrew Ashur, CEO, Lucid Drone Technologies. “T-Mobile not only allows us to provide our customers with the highest quality of real-time support and connectivity today, but they also have impressive 5G capabilities that allow us to push the frontier limits of responsible robotics."
“Lucid Drone Technologies is a great example of a customer using originality and new technology to solve complicated problems,” said Callie Field, President, T-Mobile Business Group. “It’s not very often that you get to collaborate with these kinds of thinkers, and we’re thrilled to have the opportunity to offer our technology to help bring their vision to life.”
To learn more about Lucid Drone Technologies, visit: www.luciddronetech.com
For more information about IoT from T-Mobile for Business, go to: www.t-mobile.com/business/solutions/iot
Follow T-Mobile’s Official Twitter Newsroom @TMobileNews to stay up to date with the latest company news.
Fastest based on median, overall combined 5G speeds according to analysis by Ookla® of Speedtest Intelligence® data 5G download speeds for Q1 2022. Ookla trademarks used under license and reprinted with permission.
About T-Mobile
T-Mobile U.S. Inc. (NASDAQ: TMUS) is America’s supercharged Un-carrier, delivering an advanced 4G LTE and transformative nationwide 5G network that will offer reliable connectivity for all. T-Mobile’s customers benefit from its unmatched combination of value and quality, unwavering obsession with offering them the best possible service experience and undisputable drive for disruption that creates competition and innovation in wireless and beyond. Based in Bellevue, Wash., T-Mobile provides services through its subsidiaries and operates its flagship brands, T-Mobile, Metro by T-Mobile and Sprint. For more information please visit: https://www.t-mobile.com .
About Lucid Drone Technologies
Lucid Drone Technologies is a Charlotte, NC-based robotics company that currently designs and builds industrial spraying drones for labor-intensive jobs. Lucid Drone Technologies was started in 2018, and set out to provide a Safer, Faster, and Smarter alternative to traditional dull, dirty, and dangerous jobs.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220424005109/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release
News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release
Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom